Episode 57: Live from Day 1 at ECTRIMS 2018 - a podcast by Jon Strum
from 2018-10-10T22:39:24
::
::
Greetings from Day 1 at ECTRIMS in Berlin! Today, we're talking about pharmaceutical company Novartis seeking approval from the U.S. Food & Drug Administration and the European Medicines Agency for siponimod, a once-daily oral medication that significantly reduces disability progression for people living with secondary progressive MS.
This is important news, as 80% of the people living with relapsing remitting MS are eventually diagnosed with secondary progressive MS. And currently, there is no approved disease modifying therapy for secondary progressive MS. The FDA has fast-tracked the approval process, and siponimod could gain the necessary regulatory approval in the U.S. by March, 2019, and in Europe by the end of 2019.
The "Welcome" session featured a short address by the Chair of the ECTRIMS 2018 conference, Professor Reinhard Hohfeld. After the session ended, Professor Hohfeld and I snuck out to the hallway for a quick conversation. You'll hear my exclusive conversation with ECTRIMS Chair Professor Reinhard Hohfeld in today's podcast episode.
Be sure to download the special ECTRIMS episodes of RealTalk MS tomorrow and Friday, as well! We have a lot to talk about!!
___________
LINKS
If your podcast app doesn’t show these links, you’ll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
Download the RealTalk MS App for iOS
Download the RealTalk MS App for Android
Novartis files for FDA & EMA Approval of Siponimod
Give RealTalk MS a Rating & Review
___________
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 57
Hosted By: Jon Strum
Guest: Professor Reinhard Hohfeld
Tags: MS, MultipleSclerosis, ECTRIMS2018, Siponimod, RealTalkMS
Further episodes of RealTalk MS
Further podcasts by Jon Strum
Website of Jon Strum